5-HT2B receptor (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "5-HT2B receptor" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

23nih.gov

4^th place

3^rd place

21doi.org

2^nd place

8archive.org

6^th place

5^th place

2web.archive.org

1^st place

1elsevier.com

610^th place

525^th place

1ahajournals.org

3,608^th place

1,651^st place

1opus-bayern.de

low place

1researchgate.net

120^th place

516^th place

1wkhealth.com

low place

2,251^st place

ahajournals.org

circ.ahajournals.org

Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, György K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, Maroteaux L (June 2001). „Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function”. Circulation 103 (24): 2973–9. PMID 11413089.

archive.org

Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (August 2008). „Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice”. Hypertension 52 (2): 301–7. DOI:10.1161/HYPERTENSIONAHA.107.105551. PMID 18591460.
Porter RH, Benwell KR, Lamb H, et al. (1999). „Functional characterization of agonists at recombinant human 5-HT_2A, 5-HT_2B and 5-HT_2C receptors in CHO-K1 cells”. Br. J. Pharmacol. 128 (1): 13–20. DOI:10.1038/sj.bjp.0702751. PMC 1571597. PMID 10498829.
Kennett GA, Trail B, Bright F (December 1998). „Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated”. Neuropharmacology 37 (12): 1603–10. DOI:10.1016/S0028-3908(98)00115-4. PMID 9886683.
Görnemann T, Hübner H, Gmeiner P, et al. (2008). „Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine_2B and 5-Hydroxytryptamine_2A receptors”. J. Pharmacol. Exp. Ther. 324 (3): 1136–45. DOI:10.1124/jpet.107.133165. PMID 18096760.
Beattie DT, Smith JA, Marquess D, et al. (November 2004). „The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo”. Br. J. Pharmacol. 143 (5): 549–60. DOI:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450.
Bonhaus DW, Flippin LA, Greenhouse RJ, et al. (1999). „RS-127445: a selective, high affinity, orally bioavailable 5-HT_2B receptor antagonist”. Br. J. Pharmacol. 127 (5): 1075–82. DOI:10.1038/sj.bjp.0702632. PMC 1566110. PMID 10455251.
Dunlop J, Lock T, Jow B, et al. (March 2009). „Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b'di pyrrole-1(2H)-carboxamide)”]. J. Pharmacol. Exp. Ther. 328 (3): 766–76. DOI:10.1124/jpet.108.146514. PMID 19050173.
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (February 1999). „Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist”. Br. J. Pharmacol. 126 (3): 572–4. DOI:10.1038/sj.bjp.0702350. PMC 1565856. PMID 10188965.

doi.org

dx.doi.org

Schmuck K, Ullmer C, Engels P, Lübbert H (March 1994). „Cloning and functional characterization of the human 5-HT_2B serotonin receptor”. FEBS Lett. 342 (1): 85–90. DOI:10.1016/0014-5793(94)80590-3. PMID 8143856.
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (March 2008). „Serotonin 5-HT_2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro”. J. Neurosci. 28 (11): 2933–40. DOI:10.1523/JNEUROSCI.5723-07.2008. PMID 18337424.
Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (October 2002). „Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension”. Nat. Med. 8 (10): 1129–35. DOI:10.1038/nm764. PMID 12244304.
Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N (August 2008). „5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats”. Exp. Toxicol. Pathol. 60 (4–5): 253–62. DOI:10.1016/j.etp.2008.03.005. PMID 18511249.
Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L (August 2004). „Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts”. Circulation 110 (8): 969–74. DOI:10.1161/01.CIR.0000139856.20505.57. PMID 15302781.
Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (August 2008). „Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice”. Hypertension 52 (2): 301–7. DOI:10.1161/HYPERTENSIONAHA.107.105551. PMID 18591460.
Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L (November 2008). „Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy”. Circ. Res. 104 (1): 113–23. DOI:10.1161/CIRCRESAHA.108.180976. PMID 19023134.
Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L (May 2006). „Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice”. J. Pharmacol. Exp. Ther. 317 (2): 724–31. DOI:10.1124/jpet.105.098269. PMID 16461587.
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (March 2008). „Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro”. J. Neurosci. 28 (11): 2933–40. DOI:10.1523/JNEUROSCI.5723-07.2008. PMID 18337424.
Diaz SL, Maroteaux L (January 2011). „Implication of 5-HT(2B) receptors in the serotonin syndrome”. Neuropharmacology. DOI:10.1016/j.neuropharm.2011.01.025. PMID 21277875.
Porter RH, Benwell KR, Lamb H, et al. (1999). „Functional characterization of agonists at recombinant human 5-HT_2A, 5-HT_2B and 5-HT_2C receptors in CHO-K1 cells”. Br. J. Pharmacol. 128 (1): 13–20. DOI:10.1038/sj.bjp.0702751. PMC 1571597. PMID 10498829.
Kennett GA, Trail B, Bright F (December 1998). „Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated”. Neuropharmacology 37 (12): 1603–10. DOI:10.1016/S0028-3908(98)00115-4. PMID 9886683.
Setola, Vincent; Sandra J Hufeisen, K Jane Grande-Allen, Ivan Vesely, Richard A Glennon, Bruce Blough, Richard B Rothman, Bryan L Roth (2003-01-07). „3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro”. Molecular pharmacology 63 (6): 1223–1229. DOI:10.1124/mol.63.6.1223. PMID 12761331.
Ray TS; Manzoni, Olivier Jacques (2010). Manzoni, Olivier Jacques. ur. „Psychedelics and the human receptorome”. PLoS ONE 5 (2): e9019. DOI:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
Görnemann T, Hübner H, Gmeiner P, et al. (2008). „Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine_2B and 5-Hydroxytryptamine_2A receptors”. J. Pharmacol. Exp. Ther. 324 (3): 1136–45. DOI:10.1124/jpet.107.133165. PMID 18096760.
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). „Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis”. Clin Neuropharmacol 29 (2): 80–6. DOI:10.1097/00002826-200603000-00005. PMID 16614540. Arhivirano iz originala na datum 2012-03-11. Pristupljeno 2014-05-02.
Beattie DT, Smith JA, Marquess D, et al. (November 2004). „The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo”. Br. J. Pharmacol. 143 (5): 549–60. DOI:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450.
Bonhaus DW, Flippin LA, Greenhouse RJ, et al. (1999). „RS-127445: a selective, high affinity, orally bioavailable 5-HT_2B receptor antagonist”. Br. J. Pharmacol. 127 (5): 1075–82. DOI:10.1038/sj.bjp.0702632. PMC 1566110. PMID 10455251.
Kovács A, Gacsályi I, Wellmann J, et al. (2003). „Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist”. Cardiovasc Drugs Ther 17 (5–6): 427–34. DOI:10.1023/B:CARD.0000015857.96371.43. PMID 15107597.
Dunlop J, Lock T, Jow B, et al. (March 2009). „Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b'di pyrrole-1(2H)-carboxamide)”]. J. Pharmacol. Exp. Ther. 328 (3): 766–76. DOI:10.1124/jpet.108.146514. PMID 19050173.
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (February 1999). „Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist”. Br. J. Pharmacol. 126 (3): 572–4. DOI:10.1038/sj.bjp.0702350. PMC 1565856. PMID 10188965.

elsevier.com

linkinghub.elsevier.com

Schmuck K, Ullmer C, Engels P, Lübbert H (March 1994). „Cloning and functional characterization of the human 5-HT_2B serotonin receptor”. FEBS Lett. 342 (1): 85–90. DOI:10.1016/0014-5793(94)80590-3. PMID 8143856.

nih.gov

ncbi.nlm.nih.gov

„Entrez Gene: HTR_2B 5-hydroxytryptamine (serotonin) receptor 2B”.
Schmuck K, Ullmer C, Engels P, Lübbert H (March 1994). „Cloning and functional characterization of the human 5-HT_2B serotonin receptor”. FEBS Lett. 342 (1): 85–90. DOI:10.1016/0014-5793(94)80590-3. PMID 8143856.
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (March 2008). „Serotonin 5-HT_2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro”. J. Neurosci. 28 (11): 2933–40. DOI:10.1523/JNEUROSCI.5723-07.2008. PMID 18337424.
Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (October 2002). „Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension”. Nat. Med. 8 (10): 1129–35. DOI:10.1038/nm764. PMID 12244304.
Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, György K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, Maroteaux L (June 2001). „Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function”. Circulation 103 (24): 2973–9. PMID 11413089.
Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N (August 2008). „5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats”. Exp. Toxicol. Pathol. 60 (4–5): 253–62. DOI:10.1016/j.etp.2008.03.005. PMID 18511249.
Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L (August 2004). „Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts”. Circulation 110 (8): 969–74. DOI:10.1161/01.CIR.0000139856.20505.57. PMID 15302781.
Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (August 2008). „Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice”. Hypertension 52 (2): 301–7. DOI:10.1161/HYPERTENSIONAHA.107.105551. PMID 18591460.
Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L (November 2008). „Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy”. Circ. Res. 104 (1): 113–23. DOI:10.1161/CIRCRESAHA.108.180976. PMID 19023134.
Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L (May 2006). „Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice”. J. Pharmacol. Exp. Ther. 317 (2): 724–31. DOI:10.1124/jpet.105.098269. PMID 16461587.
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (March 2008). „Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro”. J. Neurosci. 28 (11): 2933–40. DOI:10.1523/JNEUROSCI.5723-07.2008. PMID 18337424.
Diaz SL, Maroteaux L (January 2011). „Implication of 5-HT(2B) receptors in the serotonin syndrome”. Neuropharmacology. DOI:10.1016/j.neuropharm.2011.01.025. PMID 21277875.
Porter RH, Benwell KR, Lamb H, et al. (1999). „Functional characterization of agonists at recombinant human 5-HT_2A, 5-HT_2B and 5-HT_2C receptors in CHO-K1 cells”. Br. J. Pharmacol. 128 (1): 13–20. DOI:10.1038/sj.bjp.0702751. PMC 1571597. PMID 10498829.
Kennett GA, Trail B, Bright F (December 1998). „Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated”. Neuropharmacology 37 (12): 1603–10. DOI:10.1016/S0028-3908(98)00115-4. PMID 9886683.
Setola, Vincent; Sandra J Hufeisen, K Jane Grande-Allen, Ivan Vesely, Richard A Glennon, Bruce Blough, Richard B Rothman, Bryan L Roth (2003-01-07). „3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro”. Molecular pharmacology 63 (6): 1223–1229. DOI:10.1124/mol.63.6.1223. PMID 12761331.
Ray TS; Manzoni, Olivier Jacques (2010). Manzoni, Olivier Jacques. ur. „Psychedelics and the human receptorome”. PLoS ONE 5 (2): e9019. DOI:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
Görnemann T, Hübner H, Gmeiner P, et al. (2008). „Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine_2B and 5-Hydroxytryptamine_2A receptors”. J. Pharmacol. Exp. Ther. 324 (3): 1136–45. DOI:10.1124/jpet.107.133165. PMID 18096760.
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). „Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis”. Clin Neuropharmacol 29 (2): 80–6. DOI:10.1097/00002826-200603000-00005. PMID 16614540. Arhivirano iz originala na datum 2012-03-11. Pristupljeno 2014-05-02.
Beattie DT, Smith JA, Marquess D, et al. (November 2004). „The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo”. Br. J. Pharmacol. 143 (5): 549–60. DOI:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450.
Bonhaus DW, Flippin LA, Greenhouse RJ, et al. (1999). „RS-127445: a selective, high affinity, orally bioavailable 5-HT_2B receptor antagonist”. Br. J. Pharmacol. 127 (5): 1075–82. DOI:10.1038/sj.bjp.0702632. PMC 1566110. PMID 10455251.
Kovács A, Gacsályi I, Wellmann J, et al. (2003). „Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist”. Cardiovasc Drugs Ther 17 (5–6): 427–34. DOI:10.1023/B:CARD.0000015857.96371.43. PMID 15107597.
Dunlop J, Lock T, Jow B, et al. (March 2009). „Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b'di pyrrole-1(2H)-carboxamide)”]. J. Pharmacol. Exp. Ther. 328 (3): 766–76. DOI:10.1124/jpet.108.146514. PMID 19050173.
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (February 1999). „Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist”. Br. J. Pharmacol. 126 (3): 572–4. DOI:10.1038/sj.bjp.0702350. PMC 1565856. PMID 10188965.

opus-bayern.de

Schuhmacher M (2007). [Chiral arylmethoxytryptamines as 5-HT_2B-receptor antagonists: synthesis, analysis and in-vitro pharmacology (German)]. Ph.D. Dissertation. University of Regensburg. pp. pages 6–17. Arhivirano iz originala na datum 2011-07-18. Pristupljeno 2008-08-11.

researchgate.net

Setola, Vincent; Sandra J Hufeisen, K Jane Grande-Allen, Ivan Vesely, Richard A Glennon, Bruce Blough, Richard B Rothman, Bryan L Roth (2003-01-07). „3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro”. Molecular pharmacology 63 (6): 1223–1229. DOI:10.1124/mol.63.6.1223. PMID 12761331.

web.archive.org

Schuhmacher M (2007). [Chiral arylmethoxytryptamines as 5-HT_2B-receptor antagonists: synthesis, analysis and in-vitro pharmacology (German)]. Ph.D. Dissertation. University of Regensburg. pp. pages 6–17. Arhivirano iz originala na datum 2011-07-18. Pristupljeno 2008-08-11.
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). „Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis”. Clin Neuropharmacol 29 (2): 80–6. DOI:10.1097/00002826-200603000-00005. PMID 16614540. Arhivirano iz originala na datum 2012-03-11. Pristupljeno 2014-05-02.

wkhealth.com

meta.wkhealth.com

Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). „Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis”. Clin Neuropharmacol 29 (2): 80–6. DOI:10.1097/00002826-200603000-00005. PMID 16614540. Arhivirano iz originala na datum 2012-03-11. Pristupljeno 2014-05-02.